Characteristics of Treatment Responders to Galantamine

2014-08-27 03:17:24 | BioPortfolio


To investigate the characteristics of treatment responders to galantamine.


The purposes of this study are:

1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks.

2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment






Samsung Medical Center
#50 Ilwon-Dong, Kangnam-Gu
Korea, Republic of




Samsung Medical Center

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:17:24-0400

Clinical Trials [478 Associated Clinical Trials listed on BioPortfolio]

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

The purpose of this study is to evaluate the combination of galantamine with nimodipine in 80 patients with mixed dementia on cognition and quality of life.

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

The purpose of this study is to explore the safety and tolerability and the efficacy of galantamine treatment in subjects with Pick Complex/ Frontotemporal Dementia (PC/FTD). The safety an...

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients a...

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment o...

A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

The purpose of this study is to evaluate the safety and effectiveness of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease usi...

PubMed Articles [955 Associated PubMed Articles listed on BioPortfolio]

A Dementia Café as a Bridgehead for Community-Inclusive Care: Qualitative Analysis of Observations by On-the-Job Training Participants in a Dementia Café.

Dementia cafés are becoming widespread as a new approach to dementia care, but their operational procedures and significance have not been adequately studied.

Experiences of People With Dementia in Pakistan: Help-Seeking, Understanding, Stigma, and Religion.

The prevalence of dementia will increase in low- and middle-income countries like Pakistan. Specialist dementia services are rare in Pakistan. Public awareness of dementia is low, and norms about fami...

The Ultimate Disaster? Dementia between Personal Experience and Social Representation.

Dementia is widely regarded as one of the greatest threats to a good and dignified life in old age, a condition so terrifying that even death appears preferable. This contribution is dedicated to a cr...

Understanding and predicting the longitudinal course of dementia.

To date, most research in dementia has focused either on the identification of dementia risk prediction or on understanding changes and predictors experienced by individuals before diagnosis. Despite ...

EEG Resting-State Networks in Dementia with Lewy Bodies Associated with Clinical Symptoms.

Dementia with Lewy bodies (DLB) is characterized by progressive cognitive decline, fluctuating cognition, visual hallucinations, rapid eye movement sleep behavior disorder, and parkinsonism. DLB is th...

Medical and Biotech [MESH] Definitions

Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA.

Tests designed to assess various aspects of neurocognitive function and/or dementia.

The most common clinical form of FRONTOTEMPORAL LOBAR DEGENERATION, this dementia presents with personality and behavioral changes often associated with disinhibition, apathy, and lack of insight.

An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)

A form of presenile DEMENTIA characterized by cortical dementia, NEUROFIBRILLARY TANGLES without SENILE PLAQUES, Fahr's type CALCINOSIS, and ATROPHY in frontotemporal or TEMPORAL LOBE.

More From BioPortfolio on "Characteristics of Treatment Responders to Galantamine"

Quick Search


Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Searches Linking to this Trial